News | Careers |Contact
Global

Good news! Great Bay Bio Rated as High-Tech Enterprise Once Again

2020-12-24

[香港，2020年12月24日] 近日，大湾生物再次获评高新技术企业。



高新技术企业属于国家级荣誉，是指在《国家重点支持的高新技术领域》内持续进行研究开发与技术成果转化，形成企业核心自主知识产权，并以此为基础开展经营活动，将重大高新技术成果转化成生产力的技术水平，属于国内领先或国际先进的企业，是知识密集、技术密集的经济实体。高新技术企业每三年重新认定一次，继2017年认定之后，大湾生物再次获得高新技术企业认定。

大湾生物始终坚持以创新驱动研发为核心竞争力，将人工智能化生物技术应用于细胞治疗、分子诊断、临床诊断等蓝海型市场，使药物开发速度更快、成本更小、风险更低。大湾生物连续获评高新技术企业，是相关部门与社会各界人士对大湾生物一直以来的技术创新能力、高端技术开放能力以及创新意识的肯定，进一步凸显了大湾生物作为国家重点支持的具有高技术、高成长性的战略性新型骨干企业的优势，为今后进一步提升企业品牌形象，提高产品市场占有率、资本价值，以及享受高新技术企业税收减免优惠政策等奠定了坚实基础。
Back
Recent News
Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026

Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026

2026-08-12
AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel

AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel

2026-08-07
Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published

Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published

2026-07-17
Global Bioprocessing Made Simpler and More Efficient
Schedule a Meeting

Schedule a Meeting

I agree to the privacy policy.

Submit
COPYRIGHT 2026 © Great Bay Bio ALL RIGHTS RESERVD.